ASX Growth Companies With High Insider Ownership You Should Know

Amidst a backdrop of geopolitical tensions in the Middle East and fluctuating oil prices, the Australian market is experiencing volatility, with the S&P/ASX 200 expected to open lower following Wall Street's decline. In such uncertain times, identifying growth companies with high insider ownership can offer insights into potential resilience and confidence within those businesses.

Top 10 Growth Companies With High Insider Ownership In Australia

Name	Insider Ownership	Earnings Growth
Wisr (ASX:WZR)	10.2%	94.2%
Titomic (ASX:TTT)	14.7%	71.3%
Starpharma Holdings (ASX:SPL)	19.3%	92%
SKS Technologies Group (ASX:SKS)	19.3%	27.7%
PDI Gold (ASX:PDI)	10.4%	63.6%
Forrestania Resources (ASX:FRS)	32.3%	126.7%
Echo IQ (ASX:EIQ)	17.6%	95.5%
Austral Resources Australia (ASX:AR1)	22.9%	28.2%
Auric Mining (ASX:AWJ)	19.7%	38.6%
Adveritas (ASX:AV1)	17.6%	82.8%

Click here to see the full list of 108 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

Guzman y Gomez (ASX:GYG)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Guzman y Gomez Limited operates quick service restaurants in Australia, Singapore, and Japan, with a market cap of A$2.76 billion.

Operations: The company generates revenue of A$551.75 million from its quick service restaurant operations across Australia, Singapore, and Japan.

Insider Ownership: 16.5%

Revenue Growth Forecast: 13.8% p.a.

Guzman y Gomez Limited, with significant insider ownership, is expanding its footprint by opening 35 new restaurants in Australia during Fiscal Year 2027. Despite a net loss of A$26.7 million for the year ended June 30, 2026, sales increased to A$520.4 million from A$427.11 million a year ago. Earnings are forecast to grow significantly over the next three years at an annual rate of 20.5%, outpacing the broader Australian market growth expectations.

• Take a closer look at Guzman y Gomez's potential here in our earnings growth report.
• Our valuation report here indicates Guzman y Gomez may be overvalued.

Liontown (ASX:LTR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Liontown Limited focuses on the exploration, evaluation, and development of mineral properties in Australia with a market capitalization of A$4.15 billion.

Operations: The company generates revenue of A$639.14 million from its activities in mineral exploration and development within Australia.

Insider Ownership: 11.2%

Revenue Growth Forecast: 20.2% p.a.

Liontown Limited, with high insider ownership, has become profitable this year, reporting A$92.55 million in net income for the year ended June 30, 2026. The company's revenue surged to A$639.14 million from A$297.57 million a year ago. Its revenue and earnings are forecast to grow significantly faster than the Australian market at annual rates of 20.2% and 28.7%, respectively, despite being recently dropped from the S&P/ASX Small Ordinaries Index and added to the S&P/ASX 100 Index.

• Click here and access our complete growth analysis report to understand the dynamics of Liontown.
• Insights from our recent valuation report point to the potential overvaluation of Liontown shares in the market.

Telix Pharmaceuticals (ASX:TLX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$5.19 billion.

Operations: The company generates revenue through its Precision Medicine segment, which accounts for $704.73 million, and its Manufacturing Solutions segment, contributing $277.07 million.

Insider Ownership: 14.8%

Revenue Growth Forecast: 13.8% p.a.

Telix Pharmaceuticals, with significant insider ownership and recent insider buying, is experiencing substantial growth. Earnings are forecast to grow at 41.8% annually, outpacing the Australian market. Despite a low projected return on equity of 14.8%, Telix's revenue is expected to reach over US$1 billion in 2026, driven by strategic collaborations and promising product developments like TLX591-Tx for prostate cancer. The appointment of David Gill as Chair underscores robust leadership amid this expansion phase.

• Unlock comprehensive insights into our analysis of Telix Pharmaceuticals stock in this growth report.
• The valuation report we've compiled suggests that Telix Pharmaceuticals' current price could be inflated.

Summing It All Up

• Delve into our full catalog of 108 Fast Growing ASX Companies With High Insider Ownership here.
• Searching for a Fresh Perspective? AI is about to change healthcare. These 130 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com